U.K. Approves Alexion’s Strensiq

Alexion reaches funding agreement with NICE and NHS England for Strensiq

Stockwinners offers winning stock research and stock and option picks since 1998

Alexion Pharmaceuticals (ALXN) announced that it has reached a national funding agreement with the National Institute for Health and Care Excellence, or NICE, and the National Health Service, or NHS, England based on a Managed Access Agreement, or MAA, which provides access to Strensiq for patients in England with pediatric-onset hypophosphatasia, or HPP, regardless of their current age.

The funding agreement was announced today in a positive final evaluation determination, or FED, issued by the NICE Highly Specialised Technologies, or HST, Evaluation Committee to recommend Strensiq according to the MAA.

#Strensiq (asfotase alfa) is an enzyme replacement therapy approved for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). 

#HPP is a genetic, chronic, progressive and life-threatening metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. HPP is characterized by low alkaline phosphatase (ALP) activity and defective bone mineralization that can lead to destruction and deformity of bones and other skeletal abnormalities, as well as systemic complications such as muscle weakness and respiratory failure leading to premature death in infants.

The MAA has been developed in collaboration between physician thought-leaders, patient groups, NHS England, and Alexion. The MAA ensures access to Strensiq for infants, children and adult patients with pediatric-onset HPP who experience the most disabling symptoms and are expected to benefit most from therapy.

ALXN has a 52-weeks trading range of $96.18 – $145.42. Shares last traded at $124.48.

To read stories similar to this, sign up for a free trial membership to Stockwinners; No credit card required. 

The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

 

Leave a Reply

Your email address will not be published.

Translate »